0 01/10/2023 30/09/2024 2024-09-30 false false false false false false false true false false false false false false false false true false No description of principal activities is disclosed 2023-10-01 Sage Accounts Production 24.0 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 10984168 2023-10-01 2024-09-30 10984168 2024-09-30 10984168 2023-09-30 10984168 2022-10-01 2023-09-30 10984168 2023-09-30 10984168 2022-09-30 10984168 bus:RegisteredOffice 2023-10-01 2024-09-30 10984168 bus:LeadAgentIfApplicable 2023-10-01 2024-09-30 10984168 bus:Director1 2023-10-01 2024-09-30 10984168 bus:Director2 2023-10-01 2024-09-30 10984168 core:RetainedEarningsAccumulatedLosses 2022-10-01 2023-09-30 10984168 core:RetainedEarningsAccumulatedLosses 2023-10-01 2024-09-30 10984168 core:WithinOneYear 2024-09-30 10984168 core:WithinOneYear 2023-09-30 10984168 core:ShareCapital 2024-09-30 10984168 core:ShareCapital 2023-09-30 10984168 core:RetainedEarningsAccumulatedLosses 2024-09-30 10984168 core:RetainedEarningsAccumulatedLosses 2023-09-30 10984168 core:ShareCapital 2022-09-30 10984168 core:RetainedEarningsAccumulatedLosses 2022-09-30 10984168 core:PreviouslyStatedAmount core:ShareCapital 2024-09-30 10984168 bus:SmallEntities 2023-10-01 2024-09-30 10984168 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 10984168 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 10984168 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 10984168 bus:AbridgedAccounts 2023-10-01 2024-09-30 10984168 1 2023-10-01 2024-09-30
Company registration number: 10984168
Astute Medical Education Limited
Unaudited filleted abridged financial statements
30 September 2024
Astute Medical Education Limited
Contents
Directors and other information
Accountants report
Abridged statement of financial position
Statement of changes in equity
Notes to the financial statements
Astute Medical Education Limited
Directors and other information
Directors Mr Roderick Ball
Mr James Seed
Company number 10984168
Registered office Cornerstones
52-54 Aylesbury End
Beaconsfield
Buckinghamshire
HP9 1LW
Business address Cornerstones
52-54 Aylesbury End
Beaconsfield
Buckinghamshire
HP9 1LW
Accountants Spiers and Company
72 Fielding Road
Chiswick
London
W4 1DB
Astute Medical Education Limited
Chartered accountants report to the board of directors on the preparation of the
unaudited statutory financial statements of Astute Medical Education Limited
Year ended 30 September 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Astute Medical Education Limited for the year ended 30 September 2024 which comprise the abridged statement of financial position, statement of changes in equity and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com /en/members/regulations-standards-and-guidance/.
This report is made solely to the board of directors of Astute Medical Education Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Astute Medical Education Limited and state those matters that we have agreed to state to the board of directors of Astute Medical Education Limited as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Astute Medical Education Limited and its board of directors as a body for our work or for this report.
It is your duty to ensure that Astute Medical Education Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Astute Medical Education Limited. You consider that Astute Medical Education Limited is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of Astute Medical Education Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
Spiers and Company
Chartered Accountants
72 Fielding Road
Chiswick
London
W4 1DB
12 February 2025
Astute Medical Education Limited
Abridged statement of financial position
30 September 2024
2024 2023
Note £ £ £ £
Current assets
Debtors 6 -
Cash at bank and in hand 120,803 117,366
_______ _______
120,809 117,366
Creditors: amounts falling due
within one year ( 1,291) ( 80)
_______ _______
Net current assets 119,518 117,286
_______ _______
Total assets less current liabilities 119,518 117,286
_______ _______
Net assets 119,518 117,286
_______ _______
Capital and reserves
Called up share capital 100 100
Profit and loss account 119,418 117,186
_______ _______
Shareholders funds 119,518 117,286
_______ _______
For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of comprehensive income has not been delivered.
All of the members have consented to the preparation of the abridged statement of comprehensive income and the abridged statement of financial position for the current year ending 30 September 2024 in accordance with Section 444(2A) of the Companies Act 2006.
These financial statements were approved by the board of directors and authorised for issue on 12 February 2025 , and are signed on behalf of the board by:
Mr James Seed
Director
Company registration number: 10984168
Astute Medical Education Limited
Statement of changes in equity
Year ended 30 September 2024
Called up share capital Profit and loss account Total
£ £ £
At 1 October 2022 100 116,847 116,947
Profit for the year 339 339
_______ _______ _______
Total comprehensive income for the year - 339 339
_______ _______ _______
At 30 September 2023 and 1 October 2023 100 117,186 117,286
Profit for the year 2,232 2,232
_______ _______ _______
Total comprehensive income for the year - 2,232 2,232
_______ _______ _______
At 30 September 2024 100 119,418 119,518
_______ _______ _______
Astute Medical Education Limited
Notes to the financial statements
Year ended 30 September 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Cornerstones, 52-54 Aylesbury End, Beaconsfield, Buckinghamshire, HP9 1LW.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Controlling party
The directors control the company by virtue of their 100% ownership of the issued ordinary share capital of the company.